FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295817297> ?p ?o ?g. }

• W4295817297 endingPage "S701" @default.
• W4295817297 startingPage "S700" @default.
• W4295817297 abstract "HER2 amplification/overexpression (HER2-positive [HER2+]) is reported in ∼3-5% of all pts with mCRC. Treatment strategies for mCRC focus on prolonging survival, delaying tumor progression, and maintaining health-related quality of life (HRQoL). Tucatinib (TUC) is a highly selective, HER2-directed, tyrosine kinase inhibitor. Results from the MOUNTAINEER (NCT03043313) study demonstrated that dual HER2 inhibition with TUC and trastuzumab (T) in pts with HER2+ RAS WT mCRC is well tolerated with durable clinical benefit. Here we report the impact of TUC + T on HRQoL in pts from MOUNTAINEER. MOUNTAINEER is a global, multi-center, open-label, phase 2 trial that enrolled pts with HER2+ RAS WT mCRC previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and anti-VEGF mAb. Overall, 117 pts were enrolled or randomized to receive TUC + T (cohorts A [n=45] and B [n=41]) or TUC monotherapy (cohort C [n=31]). HRQoL was assessed with EQ-5D-5L and EORTC QLQ-C30 for cohorts B and C. Cohort A was not assessed for HRQoL. Questionnaires were administered at predose on Cycle 1 Day 1 (C1 D1), C1 D8, C1 D15, then every D1 of C2-4 and every 3 following cycles until end of treatment. HRQoL data for cohorts B and C were analyzed using descriptive statistics. Thirty-seven pts in cohort B and 28 pts in cohort C had ≥1 dose of study treatment and completed baseline and at least 1 follow-up HRQoL assessment. For both cohorts, the mean changes from baseline during the treatment period for EORTC QLQ-C30 generally remained stable across all scales, including global health status/QoL and functional domains. Descriptive analyses showed some fluctuations in observed individual domain scores; however, global health status/QoL remained stable over time. EQ-5D-5L VAS scores also remained similar over time. HRQoL was maintained for pts treated with TUC + T or TUC monotherapy throughout the treatment period. These results, together with the primary efficacy and safety data from MOUNTAINEER, further support the overall tolerability profile of TUC + T and suggest this regimen may be an important treatment option for pts with HER2+ mCRC." @default.
• W4295817297 created "2022-09-15" @default.
• W4295817297 creator A5005968330 @default.
• W4295817297 creator A5007810585 @default.
• W4295817297 creator A5017504528 @default.
• W4295817297 creator A5018405630 @default.
• W4295817297 creator A5026429363 @default.
• W4295817297 creator A5031031537 @default.
• W4295817297 creator A5031539570 @default.
• W4295817297 creator A5033837903 @default.
• W4295817297 creator A5036015683 @default.
• W4295817297 creator A5044831450 @default.
• W4295817297 creator A5051980146 @default.
• W4295817297 creator A5053002435 @default.
• W4295817297 creator A5054550116 @default.
• W4295817297 creator A5060994391 @default.
• W4295817297 creator A5065448100 @default.
• W4295817297 creator A5066487010 @default.
• W4295817297 creator A5073363866 @default.
• W4295817297 creator A5077382664 @default.
• W4295817297 creator A5077416215 @default.
• W4295817297 creator A5083667086 @default.
• W4295817297 date "2022-09-01" @default.
• W4295817297 modified "2023-10-14" @default.
• W4295817297 title "361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER" @default.
• W4295817297 doi "https://doi.org/10.1016/j.annonc.2022.07.499" @default.
• W4295817297 hasPublicationYear "2022" @default.
• W4295817297 type Work @default.
• W4295817297 citedByCount "0" @default.
• W4295817297 crossrefType "journal-article" @default.
• W4295817297 hasAuthorship W4295817297A5005968330 @default.
• W4295817297 hasAuthorship W4295817297A5007810585 @default.
• W4295817297 hasAuthorship W4295817297A5017504528 @default.
• W4295817297 hasAuthorship W4295817297A5018405630 @default.
• W4295817297 hasAuthorship W4295817297A5026429363 @default.
• W4295817297 hasAuthorship W4295817297A5031031537 @default.
• W4295817297 hasAuthorship W4295817297A5031539570 @default.
• W4295817297 hasAuthorship W4295817297A5033837903 @default.
• W4295817297 hasAuthorship W4295817297A5036015683 @default.
• W4295817297 hasAuthorship W4295817297A5044831450 @default.
• W4295817297 hasAuthorship W4295817297A5051980146 @default.
• W4295817297 hasAuthorship W4295817297A5053002435 @default.
• W4295817297 hasAuthorship W4295817297A5054550116 @default.
• W4295817297 hasAuthorship W4295817297A5060994391 @default.
• W4295817297 hasAuthorship W4295817297A5065448100 @default.
• W4295817297 hasAuthorship W4295817297A5066487010 @default.
• W4295817297 hasAuthorship W4295817297A5073363866 @default.
• W4295817297 hasAuthorship W4295817297A5077382664 @default.
• W4295817297 hasAuthorship W4295817297A5077416215 @default.
• W4295817297 hasAuthorship W4295817297A5083667086 @default.
• W4295817297 hasBestOaLocation W42958172971 @default.
• W4295817297 hasConcept C121608353 @default.
• W4295817297 hasConcept C126322002 @default.
• W4295817297 hasConcept C143998085 @default.
• W4295817297 hasConcept C159110408 @default.
• W4295817297 hasConcept C2779786085 @default.
• W4295817297 hasConcept C2779951463 @default.
• W4295817297 hasConcept C2780259306 @default.
• W4295817297 hasConcept C2780962732 @default.
• W4295817297 hasConcept C526805850 @default.
• W4295817297 hasConcept C530470458 @default.
• W4295817297 hasConcept C71924100 @default.
• W4295817297 hasConcept C72563966 @default.
• W4295817297 hasConceptScore W4295817297C121608353 @default.
• W4295817297 hasConceptScore W4295817297C126322002 @default.
• W4295817297 hasConceptScore W4295817297C143998085 @default.
• W4295817297 hasConceptScore W4295817297C159110408 @default.
• W4295817297 hasConceptScore W4295817297C2779786085 @default.
• W4295817297 hasConceptScore W4295817297C2779951463 @default.
• W4295817297 hasConceptScore W4295817297C2780259306 @default.
• W4295817297 hasConceptScore W4295817297C2780962732 @default.
• W4295817297 hasConceptScore W4295817297C526805850 @default.
• W4295817297 hasConceptScore W4295817297C530470458 @default.
• W4295817297 hasConceptScore W4295817297C71924100 @default.
• W4295817297 hasConceptScore W4295817297C72563966 @default.
• W4295817297 hasLocation W42958172971 @default.
• W4295817297 hasOpenAccess W4295817297 @default.
• W4295817297 hasPrimaryLocation W42958172971 @default.
• W4295817297 hasRelatedWork W2023346450 @default.
• W4295817297 hasRelatedWork W2035805452 @default.
• W4295817297 hasRelatedWork W2051540233 @default.
• W4295817297 hasRelatedWork W2058385450 @default.
• W4295817297 hasRelatedWork W2080692829 @default.
• W4295817297 hasRelatedWork W2085015240 @default.
• W4295817297 hasRelatedWork W2169358424 @default.
• W4295817297 hasRelatedWork W2577979650 @default.
• W4295817297 hasRelatedWork W2941876474 @default.
• W4295817297 hasRelatedWork W349909140 @default.
• W4295817297 hasVolume "33" @default.
• W4295817297 isParatext "false" @default.
• W4295817297 isRetracted "false" @default.
• W4295817297 workType "article" @default.